21.06.2011 • News

Trial Set For Teva-Mylan Copaxone Lawsuit

A U.S. court on Friday denied a motion by Teva Pharmaceutical Industries for summary judgment in the Copaxone patent infringement lawsuit it has brought against Mylan Inc.    

Teva is suing generic drugmaker Mylan for infringement of patents covering Teva's top-selling Copaxone multiple sclerosis drug.      

Mylan said on Friday that the U.S. District Court for the Southern District of New York has denied Teva's motion for summary judgment.      

In addition, the court set a start date of July 11 for the trial regarding Mylan's inequitable conduct affirmative defense.      

The remaining issues will be tried beginning Sept. 7, Mylan said in a statement.      

The potential for a generic Copaxone is a major issue weighing on shares of Israel-based Teva.

 

 

 

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Top-Feature

most read